Apimeds Pharmaceuticals US (APUS) EBT (2024 - 2025)

Apimeds Pharmaceuticals US (APUS) posted EBT of -$7.3 million for Q4 2025, down 305.91% on a QoQ basis from -$1.8 million in Q3 2025, and down 1797.17% year-over-year from $429099.8 in Q4 2024.

Apimeds Pharmaceuticals US (APUS) EBT (2024 - 2025) Analysis & Trends

Apimeds Pharmaceuticals US's EBT history runs 2 years deep, the most recent figure standing at -$7.3 million for Q4 2025.

  • Quarterly EBT fell 1797.17% year-over-year to -$7.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$12.2 million (down 730.98% YoY) and the FY2025 annual result came in at -$14.5 million, down 498.81% from the prior year.
  • EBT was -$7.3 million for Q4 2025 at Apimeds Pharmaceuticals US, down from -$1.8 million in the prior quarter.
  • Across five years, EBT topped out at -$296473.0 in Q1 2024 and bottomed at -$7.3 million in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBT (Qtr)
1 Haleon 88.07 Bn 86.20 Bn - -
2 Teva Pharmaceutical Industries 35.75 Bn 32.01 Bn 1.97 Bn 437.00 Mn
3 Zoetis 31.84 Bn 29.90 Bn 1.62 Bn 758.00 Mn
4 Takeda Pharmaceutical 27.18 Bn 23.12 Bn 4.39 Bn -2.90 Bn
5 United Therapeutics 23.09 Bn 20.93 Bn 648.10 Mn 318.30 Mn
6 RedHill Biopharma 21.32 Bn 21.32 Bn - -
7 Viatris 19.96 Bn 18.16 Bn 1.16 Bn -247.30 Mn
8 Neurocrine Biosciences 17.66 Bn 16.34 Bn 800.70 Mn 246.80 Mn
9 Elanco Animal Health 12.44 Bn 12.02 Bn 785.00 Mn 87.00 Mn
10 Apimeds Pharmaceuticals US 61.48 Mn 61.48 Mn - -7.28 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 -7.28 Mn
Sep 30, 2025 -1.79 Mn
Jun 30, 2025 -2.67 Mn
Mar 31, 2025 -402,397.00
Dec 31, 2024 -383,864.00
Sep 30, 2024 -332,521.00
Jun 30, 2024 -449,363.00
Mar 31, 2024 -296,473.00